
|Videos|July 15, 2021
Metastatic urothelial carcinoma: Is addition of more therapies to treatment regimens beneficial?
Author(s)Urology Times staff
Shilpa Gupta, MD, discusses several recent studies in the metastatic urothelial carcinoma space.
Advertisement
In this video, Shilpa Gupta, MD, discusses how recent research appears to indicate that the addition of more agents is not beneficial to patients undergoing treatment for metastatic urothelial carcinoma. Gupta is the Director of the Genitourinary Medical Oncology at Taussig Cancer Institute and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Datopotamab deruxtecan enters phase 3 trial in high-risk muscle-invasive urothelial cancer
2
Pearls & Perspectives: From Emergency Medicine to Sexual Medicine, With Jeff Myers, DO
3
Nicole L. Miller, MD, FACS, on persistent LUTS after BPH treatment
4
AI system links surgical gestures with postoperative outcomes
5












